Insider Selling: Jazz Pharmaceuticals (JAZZ) SVP Sells $620,400.00 in Stock

Jazz Pharmaceuticals (NASDAQ:JAZZ) SVP Karen J. Wilson sold 3,760 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, May 11th. The stock was sold at an average price of $165.00, for a total value of $620,400.00. Following the transaction, the senior vice president now owns 15,811 shares in the company, valued at approximately $2,608,815. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

NASDAQ:JAZZ opened at $165.01 on Friday. Jazz Pharmaceuticals has a 52 week low of $160.05 and a 52 week high of $163.09. The company has a current ratio of 3.00, a quick ratio of 2.88 and a debt-to-equity ratio of 0.55. The firm has a market capitalization of $9.67 billion, a price-to-earnings ratio of 16.35, a price-to-earnings-growth ratio of 0.83 and a beta of 0.97.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $2.58 EPS for the quarter, missing the Zacks’ consensus estimate of $2.73 by ($0.15). Jazz Pharmaceuticals had a net margin of 26.51% and a return on equity of 23.78%. The business had revenue of $436.40 million during the quarter, compared to analysts’ expectations of $440.91 million. research analysts predict that Jazz Pharmaceuticals will post 11.65 EPS for the current fiscal year.

A number of brokerages recently commented on JAZZ. B. Riley lifted their price objective on Jazz Pharmaceuticals from $206.00 to $211.00 and gave the stock a “buy” rating in a research report on Thursday, May 10th. HC Wainwright set a $160.00 price objective on Jazz Pharmaceuticals and gave the stock a “hold” rating in a research report on Wednesday, May 9th. ValuEngine upgraded Jazz Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, May 11th. BidaskClub upgraded Jazz Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday. Finally, BMO Capital Markets lifted their price objective on Jazz Pharmaceuticals from $199.00 to $201.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 9th. Seven analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. Jazz Pharmaceuticals currently has an average rating of “Buy” and an average price target of $181.60.

Hedge funds have recently bought and sold shares of the stock. US Bancorp DE raised its holdings in shares of Jazz Pharmaceuticals by 49.5% in the 4th quarter. US Bancorp DE now owns 1,087 shares of the specialty pharmaceutical company’s stock valued at $147,000 after buying an additional 360 shares during the period. We Are One Seven LLC purchased a new stake in shares of Jazz Pharmaceuticals in the 4th quarter valued at $157,000. Financial Gravity Companies Inc. raised its holdings in shares of Jazz Pharmaceuticals by 124.6% in the 1st quarter. Financial Gravity Companies Inc. now owns 1,271 shares of the specialty pharmaceutical company’s stock valued at $192,000 after buying an additional 705 shares during the period. Brighton Jones LLC purchased a new stake in shares of Jazz Pharmaceuticals in the 1st quarter valued at $205,000. Finally, Invictus RG purchased a new stake in shares of Jazz Pharmaceuticals in the 4th quarter valued at $206,000. Hedge funds and other institutional investors own 90.62% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Insider Buying and Selling by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply